This week we’re back to England, visiting a company in Winnersh, a countryside village not far from Reading and its famous university. There, Vernalis works to develop and commercialize therapies ranging from the common cough cold to the most recent advances in immuno-oncology.

Vernalis immuno oncology

Mission: Vernalis is a commercial stage pharma with products for cough cold, antibiotics and a migraine treatment. However, its most attractive assets are still under development. The company is running 6 programs in cancer with partners such as Servier or Novartis. Among its candidates, there’s an immuno-oncology drug, CPI-444, for renal cell carcinoma.

Comment: Vernalis counts with funds from “legendary biotech investorNeil Woodford, who is surely pleased by the progress of the company, which just received a €2.8M ($3M) milestone payment from its collaborator Corvus Pharmaceuticals after the announcement of positive Phase I/Ib data on CPI-444. Interestingly, the adenosine A2A receptor antagonist was originally investigated as a treatment for Parkinson’s.


Images by Mubus7 / Shutterstock; Labiotech Map

ADVERTISEMENT
Previous post

Gene Therapy for Rheumatoid Arthritis gets Approval to Start Clinical Trials

Next post

Microorganisms in the Library: Bringing Centuries-Old Books to Life